immune responses

免疫应答
  • 文章类型: Journal Article
    背景:电惊厥治疗(ECT)有益于治疗抵抗抑郁症(TRD)的患者,但潜在的生物过程尚不清楚。我们在32例接受ECT的TRD患者中进行了一项表观基因组关联研究,以描述ECT相关的甲基化变化。在基线(T0)和结束后1个月(T1)使用蒙哥马利-奥斯贝格抑郁量表评估疾病严重程度和ECT结局。用IlluminaInfinium甲基化EPICBeadChip阵列在T0和T1进行甲基化分析。
    结果:纵向T0-T1分析显示3个差异甲基化探针(DMPs),标称p值≤10-5,其中2个在CYB5B和PVRL4基因中注释。包括协变量,我们发现了4种症状变异的DMPs,在FAM20C中注释,EPB41、OTUB1和ADARB1,以及3个响应状态的DMP,在IQCE和FAM20C中注释了2个。区域分析显示54个差异甲基化区域(DMRs),标称p值面积≤0.05,其中9个显示调整后的p值面积≤0.10,以MCF2L注释,SLC25A24,RUNX3,MIR637,FOXK2,FAM180B,POU6F1、ALS2CL和CCRL2。考虑协变量,我们发现21个DMRs用于症状变化,26个DMRs用于反应(标称p值面积≤0.05),4表示响应的调整后p值面积≤0.10,注解在SNORD34、NLRP6、GALNT2和SFT2D3。错误发现率校正后,没有一个仍然很重要。值得注意的是,ADARB1变体与精神疾病患者的自杀企图有关,SLC25A24与行为障碍有关。在与炎症/免疫过程相关的基因中注释了几种DMPs和DMRs。对女性(n=22)的纵向分析显示,症状变化和反应状态具有统计学意义的DMRs(调整后的p值面积≤0.05)和趋势显着的DMRs(调整后的p值面积≤0.07)。在与精神疾病相关的基因中注释(ZFP57,POLD4,TRIM10,GAS7,ADORA2A,TOLLIP),创伤暴露(RIPOR2)和炎症/免疫反应(LAT,DLX4,POLD4,FAM30A,H19).对女性的通路分析揭示了转录活性的富集,生长因子,DNA维持,免疫途径包括IRF7和IRF2。
    结论:虽然在整个队列中没有发现显著的结果,这项研究提供了对ECT相关甲基化变化的见解,强调与ECT结局相关的DMP和DMRs。对女性的分析显示,与精神疾病和炎症/免疫过程相关的DMRs和途径显着。
    BACKGROUND: Electroconvulsive therapy (ECT) benefits patients with treatment-resistant depression (TRD), but the underlying biological processes are unclear. We conducted an epigenome-wide association study in 32 TRD patients undergoing ECT to depict ECT-associated methylation changes. Illness severity and ECT outcomes were assessed with the Montgomery-Åsberg Depression Rating Scale at baseline (T0) and 1 month after its end (T1). Methylation was profiled at T0 and T1 with the Illumina Infinium Methylation EPIC BeadChip array.
    RESULTS: Longitudinal T0-T1 analyses showed 3 differentially methylated probes (DMPs) with nominal p values ≤ 10-5, with 2 annotated in the genes CYB5B and PVRL4. Including covariates, we found 4 DMPs for symptoms variation, annotated in FAM20C, EPB41, OTUB1 and ADARB1, and 3 DMPs for response status, with 2 annotated in IQCE and FAM20C. Regional analysis revealed 54 differentially methylated regions (DMRs) with nominal p value area ≤ 0.05, with 9 presenting adjusted p-value area ≤ 0.10, annotated in MCF2L, SLC25A24, RUNX3, MIR637, FOXK2, FAM180B, POU6F1, ALS2CL and CCRL2. Considering covariates, we found 21 DMRs for symptoms variation and 26 DMRs for response (nominal p value area ≤ 0.05), with 4 presenting adjusted p-value area ≤ 0.10 for response, annotated in SNORD34, NLRP6, GALNT2 and SFT2D3. None remained significant after false discovery rate correction. Notably, ADARB1 variants are associated with suicide attempt in patients with psychiatric disorders, and SLC25A24 relates to conduct disorder. Several DMPs and DMRs are annotated in genes associated with inflammatory/immune processes. Longitudinal analyses on females (n = 22) revealed statistically significant DMRs (adjusted p value area ≤ 0.05) and trend-significant DMRs (adjusted p value area ≤ 0.07) for symptoms variation and response status, annotated in genes related to psychiatric disorders (ZFP57, POLD4, TRIM10, GAS7, ADORA2A, TOLLIP), trauma exposure (RIPOR2) and inflammatory/immune responses (LAT, DLX4, POLD4, FAM30A, H19). Pathway analysis on females revealed enrichment for transcriptional activity, growth factors, DNA maintenance, and immune pathways including IRF7 and IRF2.
    CONCLUSIONS: Although no significant results were found for the whole cohort, the study provides insights into ECT-associated methylation changes, highlighting DMPs and DMRs related to ECT outcomes. Analyses on females revealed significant DMRs and pathways related to psychiatric disorders and inflammatory/immune processes.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Journal Article
    循环无细胞RNA(cfRNA)是阿尔茨海默病(AD)早期诊断的潜在标志,因为它决定了基因表达水平,从一开始就深入了解病理进展。cfRNA在高加索AD患者中的概况已经被彻底调查,然而,在东盟组织中还没有研究cfRNAs的报告。这项研究检查了差距,期待支持点护理AD诊断的发展。
    cfRNA谱从20个越南血浆样品(10个可能的AD和10个年龄匹配的对照)进行表征。对RNA读数进行差异表达(DE)分析。进行加权基因相关网络分析(WGCNA)以鉴定显著共表达的基因模块。然后将这些模块的表达谱与AD状态相关联以鉴定相关模块。选择具有最高结膜内连通性(模块成员)的基因作为中心基因。将差异表达基因的转录物计数与关键AD测量-MMSE和MTA评分相关,以鉴定潜在的生物标志物。
    136个基因被鉴定为显着的AD标志(p<0.05),在AD队列中52例下调,84例上调。这些基因中有45.6%在海马中高表达,小脑,和大脑皮层。值得注意的是,所有与慢性炎症相关的标志物均上调,所有凋亡标志物均发生显著变化。发现三个共表达模块与阿尔茨海默病状态显著相关(p<0.05;R2>0.5)。对这些模块的功能富集分析揭示了与粘着斑的关联,核质运输,和金属离子反应导致细胞凋亡,提示这些途径在AD病理中的潜在参与。发现47个显著的hub基因是具有最高连通性的差异表达基因。六个重要的hub基因(CREB1,YTHDC1,IL1RL1,PHACTR2,ANKRD36B,发现RNF213)与MTA和MMSE评分显着相关。其他重要转录本(XRN1,UBB,发现CHP1,THBS1,S100A9)参与炎症和神经元死亡。总的来说,我们已经确定了血浆cf-RNA中差异表达并与炎症和细胞凋亡有关的候选转录本,这可以启动在越南和东盟国家应用cf-RNA作为AD生物标志物的进一步研究。
    UNASSIGNED: Circulating cell-free RNA (cfRNA) is a potential hallmark for early diagnosis of Alzheimer\'s Disease (AD) as it construes the genetic expression level, giving insights into the pathological progress from the outset. Profiles of cfRNA in Caucasian AD patients have been investigated thoroughly, yet there was no report exploring cfRNAs in the ASEAN groups. This study examined the gap, expecting to support the development of point-of-care AD diagnosis.
    UNASSIGNED: cfRNA profiles were characterized from 20 Vietnamese plasma samples (10 probable AD and 10 age-matched controls). RNA reads were subjected to differential expression (DE) analysis. Weighted gene correlation network analysis (WGCNA) was performed to identify gene modules that were significantly co-expressed. These modules\' expression profiles were then correlated with AD status to identify relevant modules. Genes with the highest intramodular connectivity (module membership) were selected as hub genes. Transcript counts of differentially expressed genes were correlated with key AD measures-MMSE and MTA scores-to identify potential biomarkers.
    UNASSIGNED: 136 genes were identified as significant AD hallmarks (p < 0.05), with 52 downregulated and 84 upregulated in the AD cohort. 45.6% of these genes are highly expressed in the hippocampus, cerebellum, and cerebral cortex. Notably, all markers related to chronic inflammation were upregulated, and there was a significant shift in all apoptotic markers. Three co-expressed modules were found to be significantly correlated with Alzheimer\'s status (p < 0.05; R2> 0.5). Functional enrichment analysis on these modules reveals an association with focal adhesion, nucleocytoplasmic transport, and metal ion response leading to apoptosis, suggesting the potential participation of these pathways in AD pathology. 47 significant hub genes were found to be differentially expressed genes with the highest connectivity. Six significant hub genes (CREB1, YTHDC1, IL1RL1, PHACTR2, ANKRD36B, RNF213) were found to be significantly correlated with MTA and MMSE scores. Other significant transcripts (XRN1, UBB, CHP1, THBS1, S100A9) were found to be involved in inflammation and neuronal death. Overall, we have identified candidate transcripts in plasma cf-RNA that are differentially expressed and are implicated in inflammation and apoptosis, which can jumpstart further investigations into applying cf-RNA as an AD biomarker in Vietnam and ASEAN countries.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Randomized Controlled Trial
    需要更新的疫苗策略来预防新的SARS-CoV-2变种并增加免疫逃逸。这里,介绍了灭活Omicron适应性疫苗的安全性和免疫原性信息,与CoronaVac相比。
    随机,双盲,主动控制,进行了III期临床试验,以比较改良的Omicron适应疫苗(Omicron疫苗)和授权的原型疫苗(CoronaVac®)作为加强剂量.年龄≥18岁的健康成年人,先前至少在6个月前接受过2或3剂CoronaVac(2C或3C队列)的患者,参加了以2:1(2C/3C1O/1C)的比例获得加强剂量的Omicron疫苗或CoronaVac。从先前的研究中收集了26-45岁成年人的两次初始剂量的CoronaVac(2C+0)后的备用血清。收集并分析接种后28天的免疫原性和安全性数据。主要目标之一是评估Omicron疫苗加强剂对OmicronBA.1的免疫原性优势,与CoronaVac加强剂对BA.1相比。另一个目的是评估Omicron疫苗加强剂对BA.1的免疫原性的非劣效性,与两种初始剂量的CoronaVac对祖先菌株相比。
    6月1日至7月21日,2022年,共有1500名健康成年人参加。结果表明,符合BA.1中和抗体的所有预先指定的优势标准。具体来说,在3C队列中(3C+1O与3C+1C),几何平均滴度(GMT)比率和95%置信区间(CI)为1.64(1.42,1.89),较低的95CI≥1;2C+1O与3C+1C的GMT比率为1.84(1.57,2.16)。对于血清转化率,免疫比较组之间差异较低的95CIs(2/3C+1Ovs.3C+1C)均高于0%的优势标准。然而,2C/3C+1O对BA.1和2C+0对祖先菌株的非劣性标准不满足GMT比率≥2/3的较低95CI。组间的安全性相似,没有发现安全问题。
    与CoronaVac相比,适应Omicron的疫苗具有良好的耐受性,可以引起针对Omicron的优异免疫反应,虽然它在祖先菌株方面似乎不如CoronaVac。
    https://classic.clinicaltrials.gov/ct2/show/NCT05381350?term=NCT05381350&draw=2&rank=1,标识符NCT05381350。
    Updated vaccine strategies are needed to protect against new SARS-CoV-2 variants with increased immune escape. Here, information on the safety and immunogenicity of an inactivated Omicron-adapted vaccine is presented, as compared with CoronaVac.
    A randomized, double-blind, active-controlled, phase III clinical trial was conducted to compare a modified Omicron-adapted vaccine (Omicron vaccine) with the authorized prototype vaccine (CoronaVac®) as a booster dose. Healthy adults aged ≥18 years, who have previously received 2 or 3 doses of CoronaVac (2C or 3C cohort) at least 6 months before, were enrolled to get a booster dose of Omicron vaccine or CoronaVac in a ratio of 2:1 (2C/3C+1O/1C). Back-up serums after two initial doses of CoronaVac (2C+0) for adults aged 26-45 years were collected from a previous study. Immunogenicity and safety data at 28 days after vaccination were collected and analyzed. One of the primary objectives was to evaluate the superiority of immunogenicity of Omicron vaccine booster against Omicron BA.1, compared with CoronaVac booster against BA.1. Another objective was to evaluate the non-inferiority of immunogenicity of Omicron vaccine booster against BA.1, compared with two initial doses of CoronaVac against ancestral strain.
    Between June 1st and July 21st, 2022, a total of 1,500 healthy adults were enrolled. Results show that all pre-specified superiority criteria for BA.1 neutralizing antibody were met. Specifically, within the 3C cohort (3C+1O vs. 3C+1C), the geometric mean titers\' (GMT) ratio and 95% confidence interval (CI) was 1.64 (1.42, 1.89), with the lower 95%CI ≥1; a GMT ratio of 1.84 (1.57, 2.16) was observed for 2C+1O versus 3C+1C. For seroconversion rate, the lower 95%CIs of differences between immuno-comparative groups (2/3C+1O vs. 3C+1C) were all above the superiority criterion 0%. However, the non-inferiority criterion of the lower 95%CI of GMT ratio ≥2/3 was unfulfilled for 2C/3C+1O against BA.1 versus 2C+0 against ancestral strain. Safety profiles were similar between groups, with no safety concerns identified.
    The Omicron-adapted vaccine was well-tolerated and could elicit superior immune responses as compared with CoronaVac against Omicron, while it appeared inferior to CoronaVac against ancestral strain.
    https://classic.clinicaltrials.gov/ct2/show/NCT05381350?term=NCT05381350&draw=2&rank=1, identifier NCT05381350.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Journal Article
    虽然许多用于传染病过程的贝叶斯状态空间模型侧重于人群感染动力学(例如,隔室模型),在这项工作中,我们使用这些技术检查了感染过程的演变和宿主内免疫反应的复杂性。我们提出了一个联合的贝叶斯状态空间模型,以更好地了解免疫系统如何在疾病过程中控制婴儿利什曼原虫感染。我们使用一组狗的纵向分子诊断和临床数据来描述群体进展率,并为临床疾病的重要驱动因素提供证据。在这些结果中,我们发现共同感染在疾病进展中的重要性的证据.我们还表明,随着狗在感染中的进展,寄生虫负荷受年龄的影响,杀外寄生虫药治疗现状,和血清学。此外,我们提供的证据表明,来自较早时间点的病原体负荷信息会影响其未来值,并且这种影响的大小取决于狗的临床阶段。除了表征驱动疾病进展的过程,我们预测犬利什曼病进展的个体和总体模式。我们的发现和在个体水平预测中的应用都具有直接的临床意义,提出了在兽医实践中应用的可能机会,并激发了进一步调查的动机,以更好地了解和预测疾病进展。最后,作为一种重要的人畜共患病原体,这些结果可能支持未来预防和治疗人类利什曼病的努力.
    While many Bayesian state-space models for infectious disease processes focus on population infection dynamics (eg, compartmental models), in this work we examine the evolution of infection processes and the complexities of the immune responses within the host using these techniques. We present a joint Bayesian state-space model to better understand how the immune system contributes to the control of Leishmania infantum infections over the disease course. We use longitudinal molecular diagnostic and clinical data of a cohort of dogs to describe population progression rates and present evidence for important drivers of clinical disease. Among these results, we find evidence for the importance of co-infection in disease progression. We also show that as dogs progress through the infection, parasite load is influenced by their age, ectoparasiticide treatment status, and serology. Furthermore, we present evidence that pathogen load information from an earlier point in time influences its future value and that the size of this effect varies depending on the clinical stage of the dog. In addition to characterizing the processes driving disease progression, we predict individual and aggregate patterns of Canine Leishmaniasis progression. Both our findings and the application to individual-level predictions are of direct clinical relevance, presenting possible opportunities for application in veterinary practice and motivating lines of additional investigation to better understand and predict disease progression. Finally, as an important zoonotic human pathogen, these results may support future efforts to prevent and treat human Leishmaniosis.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Journal Article
    本研究评估了生长表现,免疫反应,添加三株乳酸菌(LAB)的对虾的抗病性和肠道菌群。基础饮食(控制,CO)补充植物乳杆菌W2(LA),酸化小球菌Nj(PE),屎肠球菌LYB(EN)和氟苯尼考(FL),分别,形成三种LAB饮食(1×1010cfukg-1)和氟苯尼考饮食(15mgkg-1,阳性对照),给虾喂食42天。结果表明,特定的fic增长率,饲料效率,处理组虾对副溶血性弧菌的抗病性较对照组明显提高(P<0.05)。与对照相比,酸性磷酸酶,碱性磷酸酶,酚氧化酶,总一氧化氮合酶,过氧化物酶,超氧化物歧化酶活性,总抗氧化能力,血清中溶菌酶含量和SOD的相对表达水平,LZM,proPO,LGBP,HSP70,Imd,收费标准,Relish,TOR,4E-BP,LAB组肝胰腺中的eIF4E1α和eIF4E2基因在不同程度上增强。肠道菌群分析表明,LA和EN组显著提高了微生物的多样性和丰富度,和LAB组显着改变了虾的肠道微生物结构。在门一级,LA和PE组的Verrucomicrobiota,EN组中的Firmicutes,富集了PE和EN组的放线菌群。此外,CO组增加了潜在病原体(弧菌科和黄杆菌科)的比例。潜在的病原体(弧菌)减少,和潜在的有益细菌(Tenacibaculum,Ruegeria和Bdellovibrio)响应于饮食中的三种LAB菌株而富集。当考虑虾的肠道微生物群稳态时,植物乳杆菌和屎肠球菌的效果优于嗜酸假单胞菌。然而,由于担心屎肠球菌菌株对人类健康的潜在风险,植物乳杆菌W2比屎肠球菌LYB更适合在水产养殖中应用。综合考虑上述情况,植物乳杆菌W2可以作为更好的益生菌来提高生长性能,非特定fic免疫,抗病和促进肠道健康。
    The present study evaluated the growth performance, immune responses, disease resistance and intestinal microbiota in Penaeus vannamei fed diets supplemented with three strains of lactic acid bacteria (LAB). The basal diet (control, CO) supplemented with Lactobacillus plantarum W2 (LA), Pediococcus acidilactici Nj (PE), Enterococcus faecium LYB (EN) and florfenicol (FL), respectively, formed three LAB diets (1 × 1010 cfu kg-1) and a florfenicol diet (15 mg kg-1, positive control), were fed to shrimp for 42 days. Results indicated that specific growth rate, feed efficiency rate, and disease resistance of shrimp against Vibrio parahaemolyticus in the treatment groups were significantly improved versus the control (P < 0.05). Compared with the control, acid phosphatase, alkaline phosphatase, phenonoloxidase, total nitric oxide synthase, peroxidase, superoxide dismutase activities, total antioxidant capacity, and lysozyme content in the serum and the relative expression levels of SOD, LZM, proPO, LGBP, HSP70, Imd, Toll, Relish, TOR, 4E-BP, eIF4E1α and eIF4E2 genes in the hepatopancreas of LAB groups were enhanced to various extents. Intestinal microbiota analysis showed that the LA and EN groups significantly improved microbial diversity and richness, and LAB groups significantly altered intestinal microbial structure of shrimp. At the phylum level, the Verrucomicrobiota in the LA and PE groups, the Firmicutes in the EN group, and the Actinobacteriota in the PE and EN groups were enriched. Moreover, the CO group increased the proportion of potential pathogens (Vibrionaceae and Flavobacteriaceae). The potential pathogen (Vibrio) was reduced, and potential beneficial bacteria (Tenacibaculum, Ruegeria and Bdellovibrio) were enriched in response to dietary three strains of LAB. When the intestinal microbiota homeostasis of shrimp is considered, L. plantarum and E. faecium showed better effects than P. acidilactici. However, due to the concerns on the possible potential risks of E. faecium strains to human health, L. plantarum W2 is more suitable for application in aquaculture than E. faecium LYB. Considering collectively the above, Lactobacillus plantarum W2 could be applied as better probiotic to improve the growth performance, non-specific immunity, disease resistance and promote intestinal health of P. vannamei.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

  • 文章类型: Multicenter Study
    背景:Fontan姑息治疗后的患者代表了需要心脏移植(HTx)的儿科人群的增长,并且经常患有淋巴细胞减少(L)和/或低血色素血症,这可能会因蛋白质丢失性肠病而加剧(PLE,P).这种改变的免疫表型的HTx后效应没有得到很好的研究。
    方法:在这项对小儿心脏移植协会注册的研究中,分析了2005年至2018年间接受HTx治疗的106例Fontan患者。淋巴细胞减少和PLE对移植物存活的影响,感染,拒绝,在HTx后1年和5年分析恶性肿瘤。
    结果:注意到以下淋巴细胞减少和PLE的组合:LP,n=37;+L-P,n=23;-L+P,n=10;和-L-P,n=36。在移植后的第一年内,两组之间的移植物存活率相似(LP:86%,+L-P:86%,-L+P:87%,-L-P:89%,p=.9)。与任一PLE患者相比,-L-P患者在HTx后首次感染的自由度最大,淋巴细胞减少,或两者兼有;-L-P组的感染率为22.1%,其他组的感染率为41.4%。这些患者在HTx后的第一年感染率显着降低(LP:1.03,L-P:1,-LP:1.3,-L-P:0.3感染/年,p<.001),与非单心室CHD对照组相似(0.4感染/年)。HTx后1年和5年既不能免于排斥也不能免于恶性肿瘤,不同的群体。
    结论:Fontan患者免疫表型改变,淋巴细胞减少和/或PLE,HTX后感染的风险增加,虽然有相似的早期生存率和无排斥反应和恶性肿瘤。这些数据可能会鼓励替代免疫抑制策略,并加强对这一不断增长的患者子集的监测。
    Patients after Fontan palliation represent a growing pediatric population requiring heart transplant (HTx) and often have lymphopenia (L) and/or hypogammaglobinemia that may be exacerbated by protein-losing enteropathy (PLE, P). The post-HTx effects of this altered immune phenotype are not well studied.
    In this study of the Pediatric Heart Transplant Society Registry, 106 Fontan patients who underwent HTx between 2005 and 2018 were analyzed. The impact of lymphopenia and PLE on graft survival, infection, rejection, and malignancy was analyzed at 1 and 5 years post-HTx.
    The following combinations of lymphopenia and PLE were noted: +L+P, n = 37; +L-P, n = 23; -L+P, n = 10; and -L-P, n = 36. Graft survival between the groups was similar within the first year after transplant (+L+P: 86%, +L-P: 86%, -L+P: 87%, -L-P: 89%, p = .9). Freedom from first infection post-HTx was greatest among -L-P patients compared to patients with either PLE, lymphopenia, or both; with a 22.1% infection incidence in the -L-P group and 41.4% in all others. These patients had a significantly lower infection rate in the first year after HTx (+L+P: 1.03, +L-P: 1, -L+P: 1.3, -L-P: 0.3 infections/year, p < .001) and were similar to a non-single ventricle CHD control group (0.4 infections/year). Neither freedom from rejection nor freedom from malignancy 1 and 5 years post-HTx, differed among the groups.
    Fontan patients with altered immunophenotype, with lymphopenia and/or PLE, are at increased risk of infection post-HTx, although have similar early survival and freedom from rejection and malignancy. These data may encourage alternative immunosuppression strategies and enhanced monitoring for this growing subset of patients.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

  • 文章类型: Journal Article
    涉及最佳强度和持续时间的锻炼的运动训练可改善相对缺乏休闲能力的艾滋病毒/艾滋病感染者的心理和医学变量。这项研究旨在分析相关的心理变量以及运动强度和持续时间对感染HIV的相对休闲剥夺者的免疫反应的影响。参与者完成不同的中等强度运动(30分钟(60-80%HRmax)和45分钟(60-80%HRmax))和高强度运动10分钟(>80%HRmax)。相对休闲剥夺的等级高于“正常”水平,表明参与者之间休闲的相对剥夺。生活质量总体水平“正常”,表明生活质量并不高。压力水平在心理上被认为是低的。时间对皮质醇水平有显著影响(p<0.05)。与锻炼前相比,皮质醇水平在中等强度运动45分钟后立即下降,在高强度运动10分钟后3小时下降(p<0.05)。然而,时间及条件与时间的交互作用对IL-6和sIgA水平无显著影响(p>0.05)。尽管这项试点研究的样本量很小,结果表明,中等强度的运动可被推荐用于改善HIV感染者的健康和生活质量.
    Exercise training involving exercises of optimal intensity and duration improves psychological and medical variables in relative leisure-deprived people living with HIV/AIDS. This study aimed to analyze associated psychological variables and the effect of exercise intensity and duration on immune responses in relative leisure-deprived people infected with HIV. The participants completed different moderate-intensity exercises (30 min (60−80% HRmax) and 45 min (60−80% HRmax)) and high-intensity exercise for 10 min (>80% HRmax). Levels higher than “normal” were rated for relative leisure deprivation, indicating relative deprivation of leisure among participants. The overall level of quality of life was “normal”, indicating that quality of life was not considered high. The stress level was psychologically considered low. Time had a significant effect on cortisol levels (p < 0.05). Compared to pre-exercise, cortisol level was significantly decreased immediately after moderate exercise for 45 min and 3 h post-exercise after high-intensity exercise for 10 min (p < 0.05). However, time and the interaction of condition and time had no significant effect on IL-6 and sIgA levels (p > 0.05). Despite the small sample size of this pilot study, the results demonstrate that moderate-intensity exercise can be recommended to improve the health and quality of life of people infected with HIV.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

  • 文章类型: Journal Article
    背景:多发性硬化症(MS)的特征是中枢神经系统中涉及促炎T细胞的炎性病变。免疫失调在流行疾病中有很好的描述,但不知道这是否先于疾病发展。卡介苗(BCG)疫苗接种改善小鼠MS样疾病。在接种卡介苗的人群中,结核菌素皮肤试验(TST)为T细胞介导的免疫反应提供了一种标准化的检测方法.因此,我们假设BCG疫苗接种后TST反应的强度与随后的MS风险相关。
    方法:使用来自挪威结核病筛查计划(1963-1975)的数据,我们设计了一项基于人群的队列研究,并将之前接种过卡介苗的个体中TST反应的大小与后来通过挪威MS登记处确定的MS疾病相关联.我们拟合了Cox比例风险模型和灵活的参数生存模型来研究TST反应性,MS风险及其时间关系。
    结果:在279891名参与者(52%为女性)中,679(69%的女性)后来发展为MS。更大的TST反应性与MS风险降低相关。皮肤硬结大小每增加4毫米,MS的风险比为0.86(95%置信区间0.76-0.96),性别之间相似。TST后,这种关联的强度持续了30年以上。
    结论:在30年后,对BCG的强烈体内疫苗应答与MS风险降低相关。决定TST反应性的免疫机制表明,T细胞介导的免疫在MS发作之前数十年。
    BACKGROUND: Multiple sclerosis (MS) is characterized by inflammatory lesions in the central nervous system involving pro-inflammatory T-cells. Immune dysregulation is well described in prevalent disease, but it is not known whether this precedes disease development. Bacillus Calmette-Guérin (BCG) vaccination ameliorates MS-like disease in mice. In people vaccinated with BCG, the tuberculin skin test (TST) offers a standardized measure of a T-cell-mediated immune response. We therefore hypothesized that the strength of the TST response after BCG vaccination is associated with subsequent MS risk.
    METHODS: Using data from a Norwegian tuberculosis screening programme (1963-1975), we designed a population-based cohort study and related the size of TST reactions in individuals previously vaccinated with BCG to later MS disease identified through the Norwegian MS registry. We fitted Cox proportional hazard models and flexible parametric survival models to investigate the association between TST reactivity, MS risk and its temporal relationship.
    RESULTS: Among 279 891 participants (52% females), 679 (69% females) later developed MS. Larger TST reactivity was associated with decreased MS risk. The hazard ratio for MS per every 4-mm increase in skin induration size was 0.86 (95% confidence interval 0.76-0.96) and similar between sexes. The strength of the association persisted for >30 years after the TST.
    CONCLUSIONS: A strong in vivo vaccine response to BCG is associated with reduced MS risk >30 years later. The immunological mechanisms determining TST reactivity suggest that skewed T-cell-mediated immunity precedes MS onset by many decades.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

  • 文章类型: Journal Article
    脓毒症是世界范围内严重传染病死亡的最终共同途径。本试验旨在探讨纳米姜黄素对脓毒症危重患者血液学指标的影响。14名入住ICU的患者被随机分配到纳米姜黄素组或安慰剂组,为期10天。血液指数,血清炎症生物标志物和presepsin水平以及营养状况,在干预前以及第5天和第10天评估临床结局.白细胞,中性粒细胞,血小板,红细胞沉降率(ESR),干预10天后,与安慰剂组相比,纳米姜黄素组的白介素-8水平显着降低(分别为p=.024,p=.045,p=.017,p=.041和p=.004)。在研究结束时,与安慰剂相比,干预组的血清presepsin水平也有边际有意义的下降(p=.054)。然而,在终点,与安慰剂组相比,纳米姜黄素组的总淋巴细胞计数显著增加(p=.04).研究组之间淋巴细胞水平以及中性粒细胞/淋巴细胞和血小板/淋巴细胞的比率没有显着差异。此外,其他研究结果没有观察到显著的组间差异,干预后。总的来说,纳米姜黄素可能是脓毒症危重患者的有用辅助治疗。然而,我们建议进一步研究纳米姜黄素对脓毒症及其并发症的治疗效果.实际应用:姜黄素(1,7-双[4-羟基-3-甲氧基苯基]-1,6-庚二烯-3,5-二酮)或二阿魏酸甲烷由于其多种生物学特性而广泛用于医学。最近的证据表明,姜黄素具有多种药理活性,包括免疫调节,抗氧化剂,抗炎,抗癌,和抗微生物作用。在这项研究中,据观察,纳米姜黄素以160毫克的剂量持续10天,没有副作用,降低脓毒症患者的一些炎症因子和调节免疫反应。第一次,本试验旨在确定纳米姜黄素对血液学指标以及血清presepsin和IL-8水平的影响.
    Sepsis is the final common pathway to death for severe infectious diseases worldwide. The present trial aimed to investigate the effects of nano-curcumin supplementation on hematological indices in critically ill patients with sepsis. Fourteen ICU-admitted patients were randomly allocated into either nano-curcumin or placebo group for 10 days. The blood indices, serum levels of inflammatory biomarker and presepsin as well as nutrition status, and clinical outcomes were assessed before the intervention and on days 5 and 10. White blood cells, neutrophils, platelets, erythrocyte sedimentation rate (ESR), and the levels of interleukin-8 significantly decreased in the nano-curcumin group compared to the placebo after 10 days of intervention (p = .024, p = .045, p = .017, p = .041, and p = .004, respectively). There was also a marginal meaningful decrease in serum presepsin levels in the intervention group compared to the placebo at the end of the study (p = .054). However, total lymphocyte count showed a significant increase in the nano-curcumin group compared to the placebo at the end-point (p = .04). No significant differences were found in the level of lymphocyte and the ratios of neutrophil/lymphocyte and platelet/lymphocyte between the study groups. Moreover, no significant between-group differences were observed for other study outcomes, post-intervention. Collectively, nano-curcumin may be a useful adjuvant therapy in critically ill patients with sepsis. However, further trials are suggested to examine the effects of nano-curcumin in the management of sepsis and its complications. PRACTICAL APPLICATIONS: Curcumin (1,7-bis[4-hydroxy-3-methoxyphenyl]-1,6-heptadiene-3,5- dione) or diferuloylmethane is widely used in medicine due to its several biological properties. Recent evidence has shown that curcumin possesses multiple pharmacological activities including immune-modulatory, antioxidant, anti-inflammatory, anti-cancer, and anti-microbial effects. In this study, it was observed that nano-curcumin at a dose of 160 mg for 10 days, without side effects, reduced some inflammatory factors and regulated the immune responses in sepsis patients. For the first time, this trial was conducted to determine the effect of nano-curcumin on hematological indices and the serum levels of presepsin and IL-8.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

  • 文章类型: Published Erratum
    [这更正了文章DOI:10.3389/fimmu.2021.709861。].
    [This corrects the article DOI: 10.3389/fimmu.2021.709861.].
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

公众号